Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Immunotherapy duo shows promise for Tough-to-Treat uterine cancer

NCT ID NCT05112601

Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Sep 18, 2026 · Updated 21 times

Summary

This phase II trial is testing whether combining two immunotherapy drugs, nivolumab and ipilimumab, works better than nivolumab alone for women with recurrent endometrial cancer that has a specific DNA repair defect (dMMR). About 81 participants will receive either the combination or single drug. The goal is to see if the combo can shrink tumors or slow cancer growth better than the single drug alone.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
nivolumab and ipilimumab (immunotherapy drugs)
What this could lead to
If successful, this could provide a more effective treatment option for recurrent endometrial cancer with a specific genetic feature, potentially shrinking tumors and extending life.
What could go wrong
This is a phase II trial with only 81 participants, so results are preliminary. The combination may not be more effective than nivolumab alone and could cause additional side effects like immune-related inflammation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 81 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2022

Expected to finish

Jul 2032

An estimate. End dates often move.

Lead sponsor

A government research agency

The lead sponsor is the US National Institutes of Health.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with measurable or non-measurable (detectable) recurrent endometrial cancer * Measurable disease will be defined and monitored by RECIST v 1.1. Measurable disease is defined per RECIST 1.1 criteria as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded). Each lesion must be \>= 10 mm when measured by computed tomography (CT) or magnetic resonance imaging (MRI). Lymph nodes must be \>= 15 mm in short axis when measured by CT or MRI * Non-measurable (detectable) disease in a patient is defined in this protocol per RECIST 1.1 criteria as one who does not have measurable disease but has at least one of the following conditions: * All other lesions (or sites of disease), including small lesions (longest diameter \<10 mm or pathological lymph nodes with \>= 10 to \< 15 mm short axis), are considered non-measurable disease * Ascites and/or pleural effusion attributed to tumor * Solid and/or cystic abnormalities on radiographic imaging that do not meet RECIST 1.1 definitions for target lesions * Patients must have endometrial cancer with deficient mismatch repair system. All patients must have institutional immunohistochemistry (IHC) and/or microsatellite instability (MSI) testing to determine mismatch repair (MMR) status. MMR deficiency is defined as lack of expression of one or more mismatch repair proteins (MLH1, PMS2, MSH2, MSH6, EPCAM) by immunohistochemistry and/or presence of microsatellite instability high using the National Cancer Institute (NCI)-5plex and Promega v1.2 assays, or institutional standards (e.g. next-generation sequencing \[NGS\] panel) * Method(s) of detection of MMR deficiency will be recorded for each patient. An institutional pathology report, and additional reports if available, documenting these results must be submitted. Patients with "equivocal" results on MMR testing by immunohistochemistry may be eligible if they have documented evidence of microsatellite instability by MSI testing or by next generation sequencing assays. MMR testing by IHC may be used to resolve equivocal/indeterminate MSI results * Histologic confirmation of the original primary tumor is required (submission of pathology report(s) is required). Patients with the following histologic types are eligible: Endometrioid adenocarcinoma, mucinous adenocarcinoma, dedifferentiated/undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma, adenocarcinoma not otherwise specified (N.O.S.) * Patients may have received 1-2 prior lines of systemic therapy: * Prior anti-PD1/PD-L1 therapy is allowed if given in combination with chemotherapy or radiation therapy in adjuvant or primary metastatic/recurrent settings. Patients must have had a complete response and have disease progression/relapse with treatment-free interval of 12 months or more from last dose of therapy with immune check inhibition * Patients may have received prior radiation therapy for treatment of endometrial cancer. Prior radiation therapy may have included pelvic radiation therapy, extended field pelvic/para aortic radiation therapy, intravaginal brachytherapy, and/or palliative radiation therapy. All radiation therapy must be completed at least 4 weeks prior to registration * Patients may have received prior hormonal therapy for treatment of endometrial cancer. All hormonal therapy must be discontinued at least three weeks prior to registration * Any other prior therapy directed at the malignant tumor including chemotherapy, targeted agents, biologic agents, immunologic agents, and any investigational agents, must be discontinued at least 4 weeks prior to registration (6 weeks for nitrosoureas or mitomycin C) * Age \>= 18 * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2 * Platelets \>= 100,000/mcl * Absolute neutrophil count (ANC) \>= 1,500/mcl * Creatinine =\< 1.5 x institutional/laboratory upper limit of normal (ULN) * Total serum bilirubin level =\< 1.5 x ULN (patients with known Gilbert's disease who have bilirubin level =\<3 x ULN may be enrolled) * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =\< 3 x ULN * Adequate oxygen saturation via pulse oximeter (CTCAE v.5.0 hypoxia \< grade 2 within 28 days prior to registration) * Thyroid-stimulating hormone (TSH) within normal limits (TSH \< ULN allowed in euthyroid patients on thyroid replacement therapy). TSH testing is only required if clinically indicated * Patients must have recovered from effects of recent surgery, radiotherapy or chemotherapy. At least 4 weeks must have elapsed since major surgery * As clinically indicated, patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better and have a corrected QT (QTc) interval \< 450 msec * The effects of nivolumab, and ipilimumab on the developing human fetus are unknown. For this reason and because nivolumab and ipilimumab are known to be teratogenic, women of child-bearing potential (WOCBP) must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for 5 months after the last dose of investigational drug. Women of childbearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin \[HCG\]) within 24 hours prior to the start of nivolumab. Women must not be breastfeeding. Women who are not of childbearing potential (i.e., who are postmenopausal or surgically sterile) do not require contraception * WOCBP is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal. Menopause is defined clinically as 12 months of amenorrhea in a woman over 45 in the absence of other biological or physiological causes. In addition, women under the age of 55 must have a documented serum follicle stimulating hormone (FSH) level less than 40 mIU/mL * Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial * Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of registration are eligible for this trial * Patients with evidence of chronic hepatitis B virus (HBV) infection must have an undetectable HBV viral load on suppressive therapy, if indicated * Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load * Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression and the patient is stable off steroids for at least one month * The patient or a legally authorized representative must provide study-specific informed consent prior to study entry and, for patients treated in the United States (U.S.), authorization permitting release of personal health information * Patients with vitiligo, endocrine deficiencies including thyroiditis managed with replacement hormones including physiologic corticosteroids are eligible * Patients with rheumatoid arthritis and other arthropathies, Sjogren's syndrome and psoriasis controlled with topical medication and patients with positive serology, such as antinuclear antibodies (ANA), anti-thyroid antibodies should be evaluated for the presence of target organ involvement and potential need for systemic treatment but should otherwise be eligible Exclusion Criteria: * Patients with a diagnosis of endometrial serous carcinoma or carcinosarcoma * Patients who received prior anti-PD1/PD-L1 therapy and had grade 3-4 or recurring grade 2 immune-related toxicities that led to dose delay or discontinuation of immunotherapy due to those toxicities * Patients who received anti-CTLA-4 therapy or other immunotherapeutic agents * Patients on chronic steroid therapy except those on replacement therapy at a daily dose of 10mg or less prednisone or equivalent * Patients on immunosuppressive therapy, with the exception of: * Intra-nasal, inhaled, topical or local steroid injections * Premedication for hypersensitivity reaction * Patients with active autoimmune disease or history of autoimmune disease that might recur, which may affect vital organ function or require immune suppressive treatment including systemic corticosteroids, should be excluded. These include but are not limited to patients with a history of immune related neurologic disease, multiple sclerosis, autoimmune (demyelinating) neuropathy, Guillain-Barre syndrome, myasthenia gravis; systemic autoimmune disease such as systemic lupus erythematosus (SLE), connective tissue diseases, scleroderma, inflammatory bowel disease (IBD), Crohn's, ulcerative colitis, hepatitis; and patients with a history of toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome, or phospholipid syndrome should be excluded because of the risk of recurrence or exacerbation of disease * Patients with known immune impairment who may be unable to respond to anti-CTLA-4 antibody * Patients with uncontrolled intercurrent illness including, but not limited to: ongoing or active infection (except for uncomplicated urinary tract infection), interstitial lung disease or active, non-infectious pneumonitis, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements * Women who are pregnant or unwilling to discontinue nursing * Prior therapy with CTLA-4 inhibitors, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways * History of allergic reactions attributed to compounds of similar chemical or biologic composition to nivolumab, and/or ipilimumab including severe hypersensitivity reactions to any monoclonal antibody

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Endometrial adenocarcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Carcinoma, Endometrioid endometrial carcinoma endometrial clear cell adenocarcinoma endometrial endometrioid adenocarcinoma endometrial mixed adenocarcinoma endometrial mucinous adenocarcinoma endometrial undifferentiated carcinoma endometrioid adenocarcinoma endometrium adenocarcinoma endometrium neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Endometrial adenocarcinoma Endometrial clear cell adenocarcinoma Endometrial dedifferentiated carcinoma Endometrial endometrioid adenocarcinoma Endometrial mixed cell adenocarcinoma Endometrial mucinous adenocarcinoma Endometrial undifferentiated carcinoma Endometrioid adenocarcinoma Recurrent endometrial carcinoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    133 sites. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Abbott-Northwestern Hospital

    RECRUITING

    Minneapolis, Minnesota, 55407, United States

  • Arnold Palmer Cancer Center Medical Oncology Norwin

    RECRUITING

    N. Huntingdon, Pennsylvania, 15642, United States

    Contact Email: •••••@•••••

  • Augusta University Medical Center

    RECRUITING

    Augusta, Georgia, 30912, United States

  • Beacon Kalamazoo Cancer Center

    SUSPENDED

    Kalamazoo, Michigan, 49009, United States

  • Benefis Sletten Cancer Institute

    RECRUITING

    Great Falls, Montana, 59405, United States

    Contact Email: •••••@•••••

  • Billings Clinic Cancer Center

    RECRUITING

    Billings, Montana, 59101, United States

    Contact Email: •••••@•••••

  • Bozeman Health Deaconess Hospital

    RECRUITING

    Bozeman, Montana, 59715, United States

    Contact Email: •••••@•••••

  • Bronson Battle Creek

    RECRUITING

    Battle Creek, Michigan, 49017, United States

  • Bronson Methodist Hospital

    RECRUITING

    Kalamazoo, Michigan, 49007, United States

  • Cancer and Hematology Centers of Western Michigan - Norton Shores

    SUSPENDED

    Norton Shores, Michigan, 49444, United States

  • Carle BroMenn Medical Center

    RECRUITING

    Normal, Illinois, 61761, United States

    Contact Email: •••••@•••••

  • Carle Cancer Center

    RECRUITING

    Urbana, Illinois, 61801, United States

    Contact Email: •••••@•••••

  • Carle Cancer Institute Normal

    RECRUITING

    Normal, Illinois, 61761, United States

    Contact Email: •••••@•••••

  • Carle Physician Group-Effingham

    RECRUITING

    Effingham, Illinois, 62401, United States

    Contact Email: •••••@•••••

  • Carle Physician Group-Mattoon/Charleston

    RECRUITING

    Mattoon, Illinois, 61938, United States

    Contact Email: •••••@•••••

  • Carle at The Riverfront

    RECRUITING

    Danville, Illinois, 61832, United States

    Contact Email: •••••@•••••

  • Case Western Reserve University

    RECRUITING

    Cleveland, Ohio, 44106, United States

    Contact Email: •••••@•••••

  • Cleveland Clinic Cancer Center/Fairview Hospital

    RECRUITING

    Cleveland, Ohio, 44111, United States

    Contact Email: •••••@•••••

  • Cleveland Clinic Foundation

    RECRUITING

    Cleveland, Ohio, 44195, United States

    Contact Email: •••••@•••••

  • Community Hospital of Anaconda

    RECRUITING

    Anaconda, Montana, 59711, United States

    Contact Email: •••••@•••••

  • Community Medical Center

    RECRUITING

    Missoula, Montana, 59804, United States

    Contact Email: •••••@•••••

  • Corewell Health Grand Rapids Hospitals - Butterworth Hospital

    RECRUITING

    Grand Rapids, Michigan, 49503, United States

  • Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center

    RECRUITING

    Saint Joseph, Michigan, 49085, United States

  • Corewell Health Lakeland Hospitals - Niles Hospital

    RECRUITING

    Niles, Michigan, 49120, United States

  • Corewell Health Lakeland Hospitals - Saint Joseph Hospital

    RECRUITING

    Saint Joseph, Michigan, 49085, United States

  • Corewell Health Reed City Hospital

    RECRUITING

    Reed City, Michigan, 49677, United States

  • Duke University Medical Center

    RECRUITING

    Durham, North Carolina, 27710, United States

  • Duke Women's Cancer Care Raleigh

    RECRUITING

    Raleigh, North Carolina, 27607, United States

  • Duluth Clinic Ashland

    RECRUITING

    Ashland, Wisconsin, 54806, United States

    Contact Email: •••••@•••••

  • Essentia Health - Deer River Clinic

    RECRUITING

    Deer River, Minnesota, 56636, United States

    Contact Email: •••••@•••••

  • Essentia Health Cancer Center

    RECRUITING

    Duluth, Minnesota, 55805, United States

    Contact Email: •••••@•••••

  • Essentia Health Cancer Center-South University Clinic

    RECRUITING

    Fargo, North Dakota, 58103, United States

    Contact Email: •••••@•••••

  • Essentia Health Hibbing Clinic

    RECRUITING

    Hibbing, Minnesota, 55746, United States

  • Essentia Health Sandstone

    RECRUITING

    Sandstone, Minnesota, 55072, United States

    Contact Email: •••••@•••••

  • Essentia Health Virginia Clinic

    RECRUITING

    Virginia, Minnesota, 55792, United States

    Contact Email: •••••@•••••

  • Fairview Southdale Hospital

    RECRUITING

    Edina, Minnesota, 55435, United States

  • Fred Hutchinson Cancer Center

    ACTIVE_NOT_RECRUITING

    Seattle, Washington, 98109, United States

  • Geauga Hospital

    RECRUITING

    Chardon, Ohio, 44024, United States

    Contact Email: •••••@•••••

  • Good Samaritan Hospital - Cincinnati

    ACTIVE_NOT_RECRUITING

    Cincinnati, Ohio, 45220, United States

  • Henrico Doctor's Hospital

    RECRUITING

    Richmond, Virginia, 23229, United States

  • Hillcrest Hospital Cancer Center

    RECRUITING

    Mayfield Heights, Ohio, 44124, United States

    Contact Email: •••••@•••••

  • IRMC Cancer Center

    RECRUITING

    Indiana, Pennsylvania, 15701, United States

  • IU Health North Hospital

    SUSPENDED

    Carmel, Indiana, 46032, United States

  • Indiana University/Melvin and Bren Simon Cancer Center

    RECRUITING

    Indianapolis, Indiana, 46202, United States

    Contact Email: •••••@•••••

  • Intermountain Health West End Clinic

    RECRUITING

    Billings, Montana, 59106, United States

  • Kootenai Clinic Cancer Services - Post Falls

    RECRUITING

    Post Falls, Idaho, 83854, United States

    Contact Email: •••••@•••••

  • Kootenai Clinic Cancer Services - Sandpoint

    RECRUITING

    Sandpoint, Idaho, 83864, United States

    Contact Email: •••••@•••••

  • Kootenai Health - Coeur d'Alene

    RECRUITING

    Coeur d'Alene, Idaho, 83814, United States

    Contact Email: •••••@•••••

  • Logan Health Medical Center

    RECRUITING

    Kalispell, Montana, 59901, United States

    Contact Email: •••••@•••••

  • MU Health - University Hospital/Ellis Fischel Cancer Center

    RECRUITING

    Columbia, Missouri, 65212, United States

  • MaineHealth Maine Medical Center- Scarborough

    RECRUITING

    Scarborough, Maine, 04074, United States

    Contact Email: •••••@•••••

  • Mercy Hospital

    RECRUITING

    Coon Rapids, Minnesota, 55433, United States

  • Miami Valley Hospital South

    RECRUITING

    Centerville, Ohio, 45459, United States

    Contact Email: •••••@•••••

  • Miller-Dwan Hospital

    RECRUITING

    Duluth, Minnesota, 55805, United States

    Contact Email: •••••@•••••

  • Minnesota Oncology - Edina

    RECRUITING

    Edina, Minnesota, 55435, United States

  • Munson Medical Center

    RECRUITING

    Traverse City, Michigan, 49684, United States

  • Nebraska Methodist Hospital

    RECRUITING

    Omaha, Nebraska, 68114, United States

  • Northwest Cancer Center - Crown Point

    RECRUITING

    Crown Point, Indiana, 46307, United States

    Contact Email: •••••@•••••

  • Northwest Cancer Center - Hobart

    RECRUITING

    Hobart, Indiana, 46342, United States

  • Northwest Cancer Center - Valparaiso

    RECRUITING

    Valparaiso, Indiana, 46383, United States

    Contact Email: •••••@•••••

  • Northwest Oncology LLC

    RECRUITING

    Dyer, Indiana, 46311, United States

  • Northwest Wisconsin Cancer Center

    RECRUITING

    Ashland, Wisconsin, 54806, United States

    Contact Email: •••••@•••••

  • Ohio State University Comprehensive Cancer Center

    RECRUITING

    Columbus, Ohio, 43210, United States

  • Oklahoma Cancer Specialists and Research Institute-Tulsa

    ACTIVE_NOT_RECRUITING

    Tulsa, Oklahoma, 74146, United States

  • Park Nicollet Clinic - Saint Louis Park

    RECRUITING

    Saint Louis Park, Minnesota, 55416, United States

  • Parkland Memorial Hospital

    RECRUITING

    Dallas, Texas, 75235, United States

    Contact Email: •••••@•••••

  • Providence Portland Medical Center

    RECRUITING

    Portland, Oregon, 97213, United States

    Contact Email: •••••@•••••

  • Providence Saint Vincent Medical Center

    RECRUITING

    Portland, Oregon, 97225, United States

    Contact Email: •••••@•••••

  • Regions Hospital

    RECRUITING

    Saint Paul, Minnesota, 55101, United States

  • Roswell Park Cancer Institute

    ACTIVE_NOT_RECRUITING

    Buffalo, New York, 14263, United States

  • Saint Alphonsus Cancer Care Center-Boise

    SUSPENDED

    Boise, Idaho, 83706, United States

  • Saint Alphonsus Cancer Care Center-Caldwell

    SUSPENDED

    Caldwell, Idaho, 83605, United States

  • Saint Alphonsus Cancer Care Center-Nampa

    SUSPENDED

    Nampa, Idaho, 83687, United States

  • Saint Alphonsus Cancer Care Center-Ontario

    SUSPENDED

    Ontario, Oregon, 97914, United States

  • Saint Catherine Hospital

    RECRUITING

    Indianapolis, Indiana, 46312, United States

  • Saint Francis Regional Medical Center

    RECRUITING

    Shakopee, Minnesota, 55379, United States

  • Saint Luke's Cancer Institute - Boise

    RECRUITING

    Boise, Idaho, 83712, United States

  • Saint Luke's Cancer Institute - Fruitland

    RECRUITING

    Fruitland, Idaho, 83619, United States

  • Saint Luke's Cancer Institute - Meridian

    RECRUITING

    Meridian, Idaho, 83642, United States

  • Saint Luke's Cancer Institute - Nampa

    RECRUITING

    Nampa, Idaho, 83687, United States

  • Saint Mary Medical Center

    RECRUITING

    Hobart, Indiana, 46342, United States

    Contact Email: •••••@•••••

  • Saint Vincent Frontier Cancer Center

    RECRUITING

    Billings, Montana, 59102, United States

  • State University of New York Upstate Medical University

    RECRUITING

    Syracuse, New York, 13210, United States

  • Swedish Cancer Institute-Edmonds

    RECRUITING

    Edmonds, Washington, 98026, United States

  • Swedish Cancer Institute-Issaquah

    RECRUITING

    Issaquah, Washington, 98029, United States

  • Swedish Medical Center-First Hill

    RECRUITING

    Seattle, Washington, 98122, United States

  • The Community Hospital

    RECRUITING

    Munster, Indiana, 46321, United States

  • The James Graham Brown Cancer Center at University of Louisville

    RECRUITING

    Louisville, Kentucky, 40202, United States

  • Trinity Health Grand Rapids Hospital

    SUSPENDED

    Grand Rapids, Michigan, 49503, United States

  • Trinity Health Muskegon Hospital

    SUSPENDED

    Muskegon, Michigan, 49444, United States

  • UH Seidman Cancer Center at Lake Health Mentor Campus

    RECRUITING

    Mentor, Ohio, 44060, United States

    Contact Email: •••••@•••••

  • UH Seidman Cancer Center at Saint John Medical Center

    RECRUITING

    Westlake, Ohio, 44145, United States

    Contact Email: •••••@•••••

  • UHHS-Chagrin Highlands Medical Center

    RECRUITING

    Beachwood, Ohio, 44122, United States

    Contact Email: •••••@•••••

  • UPMC Cancer Center at UPMC Horizon

    RECRUITING

    Farrell, Pennsylvania, 16121, United States

  • UPMC Cancer Center at UPMC McKeesport

    RECRUITING

    McKeesport, Pennsylvania, 15132, United States

  • UPMC Cancer Center at UPMC Northwest

    RECRUITING

    Seneca, Pennsylvania, 16346, United States

  • UPMC Cancer Center-Natrona Heights

    RECRUITING

    Natrona Heights, Pennsylvania, 15065, United States

  • UPMC Cancer Center-Washington

    RECRUITING

    Washington, Pennsylvania, 15301, United States

  • UPMC Cancer Centers - Arnold Palmer Pavilion

    RECRUITING

    Greensburg, Pennsylvania, 15601, United States

  • UPMC Hillman Cancer Center

    RECRUITING

    Pittsburgh, Pennsylvania, 15232, United States

  • UPMC Hillman Cancer Center - Monroeville

    RECRUITING

    Monroeville, Pennsylvania, 15146, United States

    Contact Email: •••••@•••••

  • UPMC Hillman Cancer Center - New Castle

    RECRUITING

    New Castle, Pennsylvania, 16105, United States

  • UPMC Hillman Cancer Center - Part of Frick Hospital

    RECRUITING

    Mount Pleasant, Pennsylvania, 15666, United States

  • UPMC Hillman Cancer Center - Passavant - Cranberry

    RECRUITING

    Cranberry Township, Pennsylvania, 16066, United States

  • UPMC Hillman Cancer Center Erie

    RECRUITING

    Erie, Pennsylvania, 16505, United States

    Contact Email: •••••@•••••

  • UPMC Hillman Cancer Center at Butler Health System

    RECRUITING

    Butler, Pennsylvania, 16001, United States

  • UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion

    RECRUITING

    Mechanicsburg, Pennsylvania, 17050, United States

  • UPMC Hillman Cancer Center in Coraopolis

    RECRUITING

    Moon Township, Pennsylvania, 15108, United States

  • UPMC West Mifflin-Cancer Center Jefferson

    RECRUITING

    West Mifflin, Pennsylvania, 15122, United States

  • UPMC-Heritage Valley Health System Beaver

    RECRUITING

    Beaver, Pennsylvania, 15009, United States

  • UPMC-Johnstown/John P. Murtha Regional Cancer Center

    RECRUITING

    Johnstown, Pennsylvania, 15901, United States

  • UPMC-Magee Womens Hospital

    RECRUITING

    Pittsburgh, Pennsylvania, 15213, United States

  • UPMC-Mercy Hospital

    RECRUITING

    Pittsburgh, Pennsylvania, 15219, United States

  • UPMC-Passavant Hospital

    RECRUITING

    Pittsburgh, Pennsylvania, 15237, United States

  • UPMC-Saint Clair Hospital Cancer Center

    RECRUITING

    Pittsburgh, Pennsylvania, 15243, United States

  • UPMC-Saint Margaret

    RECRUITING

    Pittsburgh, Pennsylvania, 15215, United States

  • UT Southwestern Clinical Center at Richardson/Plano

    RECRUITING

    Richardson, Texas, 75080, United States

  • UT Southwestern/Simmons Cancer Center-Dallas

    RECRUITING

    Dallas, Texas, 75390, United States

    Contact Email: •••••@•••••

  • UT Southwestern/Simmons Cancer Center-Fort Worth

    RECRUITING

    Fort Worth, Texas, 76104, United States

    Contact Email: •••••@•••••

  • United Hospital

    RECRUITING

    Saint Paul, Minnesota, 55102, United States

  • University Cancer and Blood Center LLC

    SUSPENDED

    Athens, Georgia, 30607, United States

  • University Hospitals Parma Medical Center

    RECRUITING

    Parma, Ohio, 44129, United States

    Contact Email: •••••@•••••

  • University of Alabama at Birmingham Cancer Center

    RECRUITING

    Birmingham, Alabama, 35233, United States

  • University of Illinois

    SUSPENDED

    Chicago, Illinois, 60612, United States

  • University of Iowa/Holden Comprehensive Cancer Center

    RECRUITING

    Iowa City, Iowa, 52242, United States

  • University of Michigan Health - West

    RECRUITING

    Wyoming, Michigan, 49519, United States

  • University of New Mexico Cancer Center

    RECRUITING

    Albuquerque, New Mexico, 87106, United States

  • University of Oklahoma Health Sciences Center

    RECRUITING

    Oklahoma City, Oklahoma, 73104, United States

  • University of Rochester

    RECRUITING

    Rochester, New York, 14642, United States

  • University of Virginia Cancer Center

    RECRUITING

    Charlottesville, Virginia, 22908, United States

    Contact Email: •••••@•••••

  • UofL Health Medical Center Northeast

    RECRUITING

    Louisville, Kentucky, 40245, United States

    Contact Email: •••••@•••••

  • VCU Massey Comprehensive Cancer Center

    ACTIVE_NOT_RECRUITING

    Richmond, Virginia, 23298, United States

  • Washington University School of Medicine

    RECRUITING

    St Louis, Missouri, 63110, United States

    Contact Email: •••••@•••••

  • West Michigan Cancer Center

    RECRUITING

    Kalamazoo, Michigan, 49007, United States

  • Wilmot Cancer Institute at Webster

    RECRUITING

    Webster, New York, 14580, United States

    Contact Email: •••••@•••••

  • Women and Infants Hospital

    RECRUITING

    Providence, Rhode Island, 02905, United States

  • Women's Cancer Center of Nevada

    RECRUITING

    Las Vegas, Nevada, 89106, United States

  • Women's Diagnostic Center - Munster

    RECRUITING

    Munster, Indiana, 46321, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.